A Randomized Trial Comparing the ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Arterial occlusive disorders; Vascular restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMPERIAL
- Sponsors Boston Scientific Corporation
- 21 Feb 2017 Planned End Date changed from 1 Jan 2022 to 1 Mar 2022.
- 21 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.
- 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.